Novartis will receive extra help from the FDA during the development of its CAR-T cancer cell therapy Kymriah for follicular lymphoma, after the regulator deemed it to be an advanced regene
The FDA has approved Seattle Genetics' breast cancer drug Tukysa (tucatinib) four months early, including in certain patients whose disease has spread to the brain.
